Loading stock data…
$3.50-0.05 (-1.41%)
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.
Intensity Therapeutics, Inc. in the Healthcare sector is trading at $3.50 with a market capitalization of $12M. Wall Street consensus targets $19.33 (6 analysts), implying a +452.4% move over the next 12 months. The stock is currently near its 52-week low of $3.10, remaining 37.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.08M↓ | -$2.53M↑ | -$3.14M↓ | -$2.73M↓ | -$2.71M |
| Net Income | -$3.01M↓ | -$2.43M↑ | -$3.05M↓ | -$2.67M↓ | -$2.54M |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6,...